ArticleFrontiers in pharmacology2026
Cost-effectiveness analysis of first-line penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma in China.
Haiyan Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.